ClinicalTrials.gg
CompletedNCT03334448Updated May 1, 2020Results posted

A Study to Compare 2 Formulations of LY900014 in Healthy Participants

A Phase 1 interventional study of LY900014-U200 and LY900014-U100 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The study involves a comparison of a LY900014 U-200 formulation with a LY900014 U-100 formulation. LY900014 is a type of fast acting insulin. Study participants will be administered LY900014 U-100 two times and LY900014 U-200 two times, over 4 study periods, by injection under the skin. Blood samples will be taken to compare how the body handles the study drugs and how they affect the blood sugar levels. Side effects and tolerability will be documented. The study will last about 4 weeks, not including screening and follow up. Screening is required within 28 days prior to the start of the study and follow up is required at least 2 weeks after the last dose of study drug.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or a female (not pregnant and agreeable to take measures until study completion)
  • Have a (BMI) of 18 to 30 kilogram per square meter (kg/m²)
  • Have normal blood pressure, pulse rate, (ECG), blood and urine laboratory test results that are acceptable for the study
  • Have veins suitable for easy blood collection and glucose solution infusion

Exclusion criteria

Exclusion Criteria:

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Had blood loss of more than 450 milliliters (mL) within the last 3 months
  • Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female)
  • Smoke more than 10 cigarettes per day
  • Are infected with or (HIV)
  • Are taking illegal drugs
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    LY900014-U200

    Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods

    Drug: LY900014-U200

  • Experimental
    LY900014-U100

    Single SC dose of 15 U LY900014 U-100 in two of four study periods

    Drug: LY900014-U100

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10])

    Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC\[0-10h\])

    Time frame: Predose, 5 minutes (mn), 10mn, 15mn, 20mn, 25mn, 30mn, 35mn, 40mn, 45 mn, 50mn, 55 mn, 60mn, 70mn,90mn,120mn,150mn,180mn, 240mn,300mn,360mn,320mn, 480mn, 540mn, and 600mn (10 hours)

Secondary outcomes

  1. Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm

    Glucodynamics: Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure.

    Time frame: Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose

07

Results

Posted May 1, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12121312
Received at least 1 dose of study drug12121312
Completed12121312
Not completed0000
Washout
Participant flow — Washout
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12121312
Completed12121312
Not completed0000
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12121312
Received at least 1 dose of study drug12121312
Completed12121312
Not completed0000
Washout
Participant flow — Washout
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12121312
Completed12111312
Not completed0100
Withdrew: Personal reason0100
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12111312
Received at least 1 dose of study drug12111312
Completed12111312
Not completed0000
Washout
Participant flow — Washout
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12111312
Completed12111311
Not completed0001
Withdrew: Protocol violation0001
Period 4
Participant flow — Period 4
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12111311
Received at least 1 dose of study drug12111311
Completed12111311
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10])

Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC\[0-10h\])

Time frame:
Predose, 5 minutes (mn), 10mn, 15mn, 20mn, 25mn, 30mn, 35mn, 40mn, 45 mn, 50mn, 55 mn, 60mn, 70mn,90mn,120mn,150mn,180mn, 240mn,300mn,360mn,320mn, 480mn, 540mn, and 600mn (10 hours)
Reported as:
Geometric mean · hours times picomols per milliliter
Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10])
hours times picomols per milliliterLY900014-U100LY900014-U200
Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10])1760 ± 191550 ± 42
Statistical analysis
  • LY900014-U100 vs LY900014-U200 · Ratio of geometric least square means: 0.830 · 90% CI 0.818 to 0.957
SecondaryPharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm

Glucodynamics: Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure.

Time frame:
Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose
Reported as:
Geometric mean · milligrams per kilogram (mg/kg)
Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm
milligrams per kilogram (mg/kg)LY900014-U100LY900014-U200
Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm1500 ± 471410 ± 55
Statistical analysis
  • LY900014-U100 vs LY900014-U200 · Ration of lease square means: 0.97 · 90% CI 0.83 to 1.09

Adverse events

Collected over Up to 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY900014-U1000/49 (0%)0/49 (0%)32/49 (65.3%)
LY900014-U2000/49 (0%)0/49 (0%)35/49 (71.4%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLY900014-U100LY900014-U200
Injection site reactionGeneral disorders23/4916/49
Infusion site painGeneral disorders6/4910/49
Catheter site bruiseGeneral disorders6/496/49
Catheter site swellingGeneral disorders6/492/49
Infusion site bruisingGeneral disorders3/496/49
Infusion site swellingGeneral disorders5/494/49
Catheter site painGeneral disorders4/492/49
PyrexiaGeneral disorders3/492/49
HeadacheNervous system disorders3/491/49
CoughRespiratory, thoracic and mediastinal disorders1/493/49

Baseline characteristics

All randomized participant who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Overall
Mean39.7 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female5
Male44
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino0
Not Hispanic or Latino49
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian47
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall
Singapore49
Weight
Weight(kilograms (kg))Overall
Mean72.16 ± 10.97
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Singapore, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Mar 2018, 3 months.

Results were first posted in May 2020, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2017
First posted
Nov 7, 2017
StartActual
Dec 4, 2017
Primary completionActual
Mar 15, 2018
CompletionActual
Mar 15, 2018
Results first posted
May 1, 2020
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03334448
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Dec 4, 2017
Primary completion
Mar 15, 2018
Completion
Mar 15, 2018
Results posted
May 1, 2020
Last update
May 1, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Lispro

Start the discussion